More News! 7 Mar 2017 UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […] March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 3 Mar 2017 Plants go Electronic with new Swedish Magic Sauce e-Plants can become a reality with a new technique that creates in vivo electronic circuits. But what are these bioelectronic plants for? A research team from the Linköping University has developed a ‘magic sauce’ that can transform the normal vascular system, through which they transport water and nutrients from the roots, into an electronic circuit. […] March 3, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2017 German Spin-off Scores Funding to Treat Atrial Fibrillation The Berlin-based startup OMEICOS Therapeutics announced the first closing of a series B financing round of €8.3M and the initiation of a Phase 1 clinical trial for the treatment of atrial fibrillation. OMEICOS Therapeutics, a spin-off from the Max Delbrueck Center for Molecular Medicine in Berlin, is taking the next step with its lead compound OMT-28 for […] March 1, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2017 Lab-Grown Meat Could Hit the Market as Soon as 2020 Cultured meat could be a sustainable, healthy and inexpensive food alternative in a future that might be closer than we think. We recently attended the 2nd International Conference on Cultured Meat, where we had the chance to meet the key players in this revolutionary field. There, we learned that cultured meat, grown in the lab without […] March 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 27 Feb 2017 UK Lays Down a Foundation for Physical Science Innovation The UK government announced a €117M (£100M) investment to join the forces in physical sciences, engineering and life sciences through the new Rosalind Franklin research institute (RFI). Rosalind Franklin, the British scientist whose use of X-rays to study biological structures played a crucial role in the discovery of the DNA ‘double helix’, has laid some of the cornerstones in biophysical […] February 27, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 27 Feb 2017 Fundraising in the UK will Support Rare Disease Diagnostics Worldwide Congenica has raised £8M in its Series B financing round to sustain the international rollout of its clinical genome analysis platform Sapientia. Congenica is a genomic diagnostics company in Cambridge’s biotech cluster. Its genome analysis platform, Sapientia, takes on the challenge of interpreting the avalanche of genomic data becoming available in healthcare. The £8M (€9.5M) raised will sustain the […] February 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 Feb 2017 Interfacing the Brain & Machines: Another Step to a Cyborg Future Controlling robotic prostheses with one’s mind has been a hot topic in research, but making a prothesis ‘talk back’ has been a stumbling block. Researchers from Switzerland show progress in creating sensations from a bidirectional neuroprosthesis. Researchers from the University of Geneva, in Switzerland, are developing a new method to connect a prosthesis to neural activity […] February 24, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 13 Feb 2017 To the Rescue: A Final Phase III Success for Post-Operative Nausea The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […] February 13, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 11 Feb 2017 This Musician Plays Piano Duets with a Microorganism Eduardo Miranda researches, composes and performs contemporary music at the interface of biology, computing and the human mind. Eduardo Miranda, Professor of Computer Music at Plymouth University, is the first person to ever compose and perform a piano piece for a human and a microorganism. To allow the tiny creature to play with him, Miranda […] February 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Feb 2017 After its First Success, the Virtual Biotech Team is Back at it Again SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […] February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The First Stroke Drug in Decades? French Biotech gets closer to the Clinic Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […] February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The FDA lays down Laws of Interchangeability: New Era for Biosimilars? The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […] February 8, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email